Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - EU Market Recap: FTSE 100 (0.22%) to 7512.96, DAX +0.04% to 16404.76, CAC40 (0.18%) to 7332.59, STOXX 600 (0.09%) to 465.78

Dec 04 ,2023

  • Synopsis:

    • European equity markets closed mixed in narrow ranges. Quiet start comes after four consecutive weeks of gains. Personal care, media and retail outperformed. Basic resources, energy and technology lagged.

    • Eurozone inflation slowed more than expected last week, which has seen hawkish policymakers warn against premature policy change (Germany's Nagel with latest). Markets are pricing in an 80% chance of ECB easing in March and 125 bps worth of rate cuts for 2024, up from 80 bps at the end of November.

    • On the macro front, German trade surplus widened amid larger drop in imports due to lower energy prices. Softer Swiss inflation data supports another SNB pause next week. Spain unemployment data worse than expected. Survey showed UK workers more confidence over job prospects.

    • In earnings, Ryanair Holdings (RYA.ID) and Wizz Air Holdings (WIZZ.LN) posted Nov passengers stats whilst Volvo Car (VOLCAR.B.SS) reported Nov car sales. Petrofac (PFC.LN) shares gained +22.4% after it released its business update saying it has a healthy pipeline scheduled for award in period to end of 2024 but no longer expects to meet guidance previously provided for full year cash flow.

    • On the M&A front, 888 (888.LN) rejected 156p/sh indicative approach from Playtech (PTEC.LN) reports the Sunday Times. Press reports also suggest UBS (UBSG.SW) to invest in US as part of strategy to garner $150B of annual new money, and CEO Ermotti aims to identify potential successor in the next three years. Roche (ROG.SW) to acquire Carmot Therapeutics (+CRMO) for $2.7B up front. Further out of DACHs, wires reported that Commerzbank (CBK.GR) has approached sovereign wealth funds to gauge their interest in buying stake of up to 9.9%.

    • In other notable company news, UCB (UCB.BB) announced EU Commission approval of Zilbrysq for the treatment of adults with generalized myasthenia gravis; Sixt (SIX2.GR) will eliminate Tesla cars from its fleet.

  • Digest:

    • Sectors - STOXX Europe 600:

      • Outperformers:

        • Personal Care Drug and Grocery Stores +0.73%, Media +0.66%, Retail +0.59%, Banks +0.45%, Health Care +0.44%, Food, Beverage and Tobacco +0.41%, Utilities +0.25%, Insurance +0.18%, Autos & Parts +0.18%, Real Estate +0.15%, Travel & Leisure +0.02%

    • Underperformers:

      • Basic Resources (2.40%), Energy(1.52%), Technology (0.81%), Construct & Mtls (0.47%), Chemicals (0.44%), Ind Goods & Svcs (0.38%), Financial Svcs (0.24%), Telecom (0.13%)

  • Macro:

    • ECB:

      • ECB's Centeno Warns That Europe's Job Market Can Go Quickly Awry - Bloomberg

      • EU laws protect Polish central bank chief, ECB's Lagarde says - Reuters

      • Poland's central bank turns to ECB in spat with Tusk - FT

    • Germany:

      • German budget crisis 'stings' already weak economy, ZEW president - Reuters

    • Portugal:

      • Banco de Portugal releases Governor Mário Centeno's analysis - link

    • UK:

      • BOE Official Urges UK to Seek Services and EU Trade Boost - Bloomberg

      • UK's Hunt says he hopes to reverse public investment freeze - Reuters

      • Britain to announce measures aimed at bringing down net migration - Reuters

      • Government consults on reforming airport slot allocation - release

      • PM Sunak considers more spending restraint to allow further tax cuts - Bloomberg

      • UK house prices likely to fall by 1% next year, says Rightmove - Guardian

    • Sovereign credit rating reviews after the close Fri included:

      • Spain A confirmed, stable trend - DBRS

      • UK AA- reaffirmed, outlook negative - Fitch

      • Ireland AA- reaffirmed, outlook positive - Fitch

      • Greece upgraded to BBB- from BB+, outlook stable - Fitch

      • France AA reaffirmed, outlook negative - S&P

  • Company news:

    • Notable Gainers

      • +22.4% PFC.LN (Petrofac £0.21, +0.04) -- business update

      • +19.1% 888.LN (888 Holdings £0.85, +0.13) -- 888 Holdings rejected 156p/share indicative approach from Playtech - Sunday Times

      • +18.6% OBI.LN (Ondine Biomedical £0.11, +0.02) -- bookbuild has now closed raising ~£2.5M

      • +17.3% ITM.LN (ITM Power £0.62, +0.09) -- H1 trading update

      • +7.4% CICN.SW (Cicor Technologies CHF50.60, +3.50) -- CMD

      • +6.1% MDM.FP (Maisons du Monde €4.88, +0.28) -- Midcap Partners upgrade

      • +4.9% LECN.SW (Leclanché CHF0.41, +0.02) -- to provide St. Kitts with 35.7 MW of solar capacity and 43.6 MWh of battery storage

      • +4.4% UCB.BB (UCB €75.02, +3.12) -- announces European Commission approval of Zilbrysq for the treatment of adults with generalized myasthenia gravis

      • +3.8% SCATC.NO (Scatec NOK74.00, +2.70) -- Scatec signs early-stage cooperation agreement with Egyptian Electricity Holding

      • +3.7% JMT.PL (Jeronimo Martins €23.58, +0.84) -- Bernstein upgrade

      • +3.7% ALBPS.FP (Biophytis €0.01, -0.00) -- company and the Univ. of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure

      • +3.6% INTRUM.SS (Intrum SEK54.34, +1.88) -- confirms in discussions regarding a potential sale of part of its back book

      • +3.1% RR.LN (Rolls-Royce Holdings £2.86, +0.09) -- JPMorgan upgrade; reinstated buy at Goldman Sachs

      • +3.1% ZEAL.DC (Zealand Pharma DKK340.40, +10.20) -- to highlight obesity pipeline at R&D Event on 5-Dec; Index change

      • +2.8% MITRA.BB (Mithra Pharmaceuticals €1.17, +0.03) -- signs binding head of terms with Gedeon Richter for a twenty-year partnership to commercialize ESTELLE and DONESTA in China

      • +2.8% SPR.LN (Springfield Properties £0.74, +0.02) -- to sell ~45 acres of land for £4.2M

      • +2.7% B2I.NO (B2 Impact NOK7.24, +0.19) -- prelim Q4 earnings

      • +2.5% NEL.NO (NEL ASA NOK8.16, +0.20) -- Index change

      • +2.5% CPI.LN (Capita £0.21, -0.00) -- to sell its 75% stake in Fera Science Limited to Bridgepoint Group for £60M

      • +2.0% HFG.GR (HelloFresh €14.54, +0.29) -- initiated outperform at Santander

      • +1.8% BOO.LN (boohoo Group £0.34, +0.01) -- Frasers Group raises stake in company to 17.2% from 16.5%

      • +1.4% DHER.GR (Delivery Hero €29.92, +0.41) -- initiated neutral at Santander

    • Notable Decliners

      • -23.7% ALPIX.FP (Pixium Vision €0.09, -0.03) -- Paris Commercial Court will hold hearing to examine takeover offer received by court-appointed administrators and to decide on outcome of company's reorganization proceedings on 18-Dec-23

      • -7.9% ALPHA.FP (Pharnext €0.00, -0.00) -- study results

      • -6.5% NOKIA.FH (Nokia €3.00, -0.21) -- circulation of reports AT&T may remove it as one of its 5G equipment suppliers

      • -4.4% PAF.LN (Pan African Resources $0.17, -0.01) -- Peel Hunt downgrade

      • -4.3% 1U1.GR (1&1 AG €16.40, -0.74) -- Goldman Sachs downgrade

      • -3.2% FUTR.LN (Future Plc £8.22, -0.27) -- Jefferies downgrade

      • -3.1% GLEN.LN (Glencore £4.43, -0.14) -- reinstated equal weight at Barclays

      • -2.7% RIO.LN (Rio Tinto $54.48, -1.51) -- approves new 12.4MW solar farm and 8.8MVa/2.1MWh of battery storage to provide renewable energy for Amrun bauxite operations (

      • -2.4% SQN.SW (Swissquote Group Holding CHF195.70, -4.90) -- Index change

      • -1.4% FLTR.LN (Flutter Entertainment £123.65, -1.80) -- Index change

  • EU companies reporting tomorrow:

    • Earnings:

      • France: Compagnie des Alpes (CDA.FP), Abeo (ABEO.FP)

      • UK: Ashtead Group (AHT.LN), Victrex (VCT.LN), SSP Group (SSPG.LN), Moonpig Group (MOON.LN), discoverIE (DSCV.LN), Marston's (MARS.LN), On The Beach (OTB.LN), Solid State (SOLI.LN), Gooch & Housego (GHH.LN), Peel Hunt Ltd. (PEEL.LN), Premier Miton (PMI.LN), CML Microsystems (CML.LN)

    • Trading Update: Nordnet (SAVE.SS), Avanza Bank Holding (AZA.SS)

    • CMD/events: Brenntag (BNR.GR), Zealand Pharma (ZEAL.DC) R&D, IWG (IWG.LN), Mercedes-Benz (MBG.GR) China boss Hubertus Troska

Data:

  • Economics:

    • Germany Oct trade balance €17.8B vs consensus €17.1B, prior revised €16.7B from €16.5B

    • Switzerland Nov CPI +1.4% y/y vs consensus +1.7%, prior +1.7%; (0.2%) m/m vs consensus (0.1%), prior +0.1%

    • Spain Nov unemployment change (24.6K) vs consensus (5.0K), prior +36.9K

    • Eurozone Dec Sentix investor confidence (16.8) vs consensus (15.0), prior (18.6)

  • Markets:

    • WTI Crude (Jan 24): ($0.54) or (0.73%) to $73.53

    • €-$ (0.0061) or (0.56%) to 1.0824

    • £-$ (0.0087) or (0.68%) to 1.2620

    • €-£ +0.0011 to 0.8576

    • S&P 500 (0.91%)

    • Performance year-to-date

      • FTSE 100: +0.82%

      • DAX: +17.82%

      • CAC: +13.27%

      • MIB: +26.20%

      • Stoxx 600: +9.62%

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE